Psychosis Psychoeducation

What matters to the person belongs at the centre of treatment

Psychosis care needs to reach beyond positive symptoms, such as hallucinations and delusions. The person may be more concerned about difficulty thinking, remembering, studying or working—or about how treatment makes them feel. These concerns should shape the conversation and the goals of care.

A wish to stop medication deserves serious discussion. We can recommend continuing treatment and explain our reasons while exploring side effects, perceived benefits and what the person hopes would change without it. Shared decision-making requires openness about these preferences, even when our recommendations differ.

Cannabis deserves the same curiosity, alongside a clear discussion of risk. Why does the person use it? When, how often, and with whom? What do they enjoy about it, and what needs does it meet? Understanding its place in their life helps us address use meaningfully and find alternatives that matter to them.

Across this issue, the guiding question is: What is getting in the way of the life this person wants—and how can treatment help?

1. Thinking clearly enough to pursue your goals

Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatric Services. 2009;60(11):1468–1476. DOI, full text.

Someone may have fewer hallucinations yet still struggle to follow a conversation, remember instructions or organise an assignment. These difficulties deserve attention in their own right.

Study and findings. This Pittsburgh trial followed 58 outpatients with early-course schizophrenia or schizoaffective disorder, allocated to cognitive enhancement therapy (31) or enriched supportive therapy (27). All continued antipsychotic treatment. Over two years, cognitive enhancement combined computer exercises with groups practising social understanding; the comparison offered education and coping support. Forty-six completed two years.

At two years, standardised differences favoured cognitive enhancement for general cognitive performance (d=0.46) and a secondary measure of social adjustment (d=1.54). These describe differences between groups on combined measures, not percentages recovered. Processing speed did not improve significantly more than with supportive therapy.

Limits. The small, selected sample excluded recent substance abuse. Some assessors knew treatment allocation, and cognitive enhancement involved more clinician contact. The package cannot tell us which ingredient helped. Its early contribution was to test cognition and everyday functioning together.

Later evidence qualified the functional result. A larger, 18-month trial involving 102 participants confirmed a cognitive benefit, but did not establish greater improvement in social adjustment than supportive therapy; attrition was substantial. Cognitive gains should therefore prompt questions about daily life, rather than a promise of functional recovery. Wojtalik and colleagues, later trial.

For families and caregivers. Start with the task the person wants to manage. If appointments are repeatedly missed, ask where the difficulty occurs: remembering the date, planning transport or getting ready to leave. Agree on a support they find useful, such as a visible calendar or a chosen reminder. These are practical applications of a cognitive perspective; they were not separately tested in this trial.

For clinicians. Our editorial reading is to connect assessment and rehabilitation to a concrete goal: following a class, completing a work task or managing appointments independently. A useful plan identifies the difficulty, the support offered, and how the person will judge whether it helps. The study tested a sustained, professionally delivered programme; a family should not have to recreate it at home.

Ask the team: What is making this particular activity difficult, and what support could help outside an appointment?

2. Understanding what cannabis contributes—and what it risks

Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(3):215–225. DOI, full text.

Cannabis may occupy an important place in someone’s life. Understanding that place helps make a discussion of risk relevant to them.

Study and findings. This synthesis combined 24 observational studies involving 16,565 people with established psychosis and at least six months of follow-up. Searches extended to April 2015. It examined cannabis use after psychosis began. Relapse definitions and follow-up periods varied.

Continued use was associated with worse relapse outcomes than non-use (d=0.36; 95% confidence interval 0.22–0.50) and discontinuation (d=0.28; 0.12–0.44). The latter comparison came from six studies reporting continued, discontinued, and non-user groups; the whole review was not its denominator. These are standardised differences, not relapse percentages. The intervals express statistical uncertainty around the group estimates.

Limits. These were associations, not random assignments to cannabis use. Medication adherence, other substances, illness differences, and changing circumstances could contribute. The review could not determine a safe THC threshold or risks for particular products. Nor did it test a cessation treatment.

For families and caregivers. Ask why, when and with whom the person uses cannabis. What do they enjoy about it? What would make reducing or stopping difficult? If it provides company, an alternative needs to address social connection. If the person uses it to manage distress or sleep, those concerns need attention too.

A jointly chosen step might be discussing sleep with the treatment team, arranging substance-use support or finding another valued evening activity. These are practical extrapolations, not interventions tested by the review.

For clinicians. Assess the substance, amount, frequency, pattern and route of use. Explore its relationship with symptoms, mood and social circumstances. Explain the association with relapse clearly, then connect the discussion to the person’s priorities. NICE guidance supports treatment for both psychosis and substance misuse, tailored to readiness for change and context.

Continued use should prompt ongoing support, not exclusion from care. Cannabis is one part of the clinical picture; its use does not justify assigning blame for relapse. NICE explicitly recommends access to mental healthcare despite coexisting substance misuse.

Ask the team: What does cannabis do for me, what risks concern us, and what help would make change more manageable?

3. A wish to stop medication belongs in the conversation

Morrison AP, Turkington D, Pyle M, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. The Lancet. 2014;383(9926):1395–1403. DOI, full text.

A person may want help while disagreeing with the proposed treatment. Their reasons deserve exploration, including when the clinician recommends continuing medication.

Study and findings. At two UK centres, 74 people who had chosen not to take antipsychotics were randomised to cognitive therapy plus usual care or usual care alone, 37 per group. Follow-up lasted 9–18 months. Therapy was offered over nine months, with later booster sessions available.

The average treatment difference across follow-up assessments favoured therapy by 6.52 points on the Positive and Negative Syndrome Scale (95% confidence interval 2.25–10.79). This scale measures psychiatric symptoms; the result is not a recovery percentage or a direct comparison with medication. Ten of 37 participants in each group started antipsychotics during the study.

Limits. The trial was small, lacked an equally intensive attention control, and had substantial missing follow-up data. It excluded acute inpatients. It could not establish who can safely remain without medication or reliably exclude uncommon serious harms.

The authors subsequently emphasised the preliminary nature of the findings and advised against stopping medication on their basis. This was a test of offering therapy to people who had declined medication, not a medication-withdrawal trial. Authors’ clarification.

For families and caregivers. Ask what the person hopes would improve without medication. What benefits have they noticed? What has become harder? Listen for specific concerns that can be brought to the prescriber. Keep a route back to help open and agree on whom to contact if difficulties increase. These are suggested approaches to engagement, not separately tested effects of the trial.

For clinicians. Recommend continued treatment when clinically indicated and explain the reasons. Explore adverse effects, perceived benefits and what the person wants to change. Discuss available options, uncertainty and follow-up, with a contingency plan appropriate to the clinical situation.

NICE guidance recommends cognitive behavioural therapy (CBT) for psychosis and medication alongside psychological interventions for acute exacerbations. Its first-episode guidance also provides for CBT and family intervention when someone still chooses psychological treatment alone, with prompt review and continued monitoring. These are UK recommendations; local care arrangements may differ.

Ask the team: What do I want to change about treatment, and how can we address that concern while planning follow-up together?

Three messages to take away

The studies answer different questions: one tested rehabilitation alongside medication, one combined observational evidence about cannabis, and one tested therapy among people declining medication. Their results cannot be used to rank these approaches against each other. Our shared practical reading is to ask what the person wants to do, what is making it difficult, and what professional support could help.

For the next appointment: What is getting in the way of the life you want—and how can treatment help?

AI and editorial disclosure

AI-assisted research and drafting. Model details were not recorded for this edition.

AI-generated content may contain errors or omissions. For education only; this does not replace individualized clinical advice or current clinical guidance.

As editor and publisher, I take editorial responsibility for published content and corrections. About this newsletter experiment and its editorial process.